Bionomics Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
10,501.30
27,108.00
46,000.40
43,423.70
25,480.50
Total Accounts Receivable
28,499.40
9,169.00
11,003.30
9,895.40
8,996.50
Inventories
83.40
409.90
438.90
425.70
490.10
Other Current Assets
433.90
1,194.00
643.20
733.70
953.30
Total Current Assets
39,518.10
37,880.90
58,085.80
54,478.40
35,920.30
Net Property, Plant & Equipment
828.40
3,450.60
2,835.10
2,617.70
2,744.20
Total Investments and Advances
-
384.00
384.00
384.00
384.00
Intangible Assets
24,714.20
27,416.30
28,504.30
26,595.00
26,017.40
Total Assets
65,060.60
69,131.70
89,809.10
84,075.10
65,065.80
ST Debt & Current Portion LT Debt
788.60
5,460.10
2,731.80
8,495.90
5,696.30
Accounts Payable
2,663.40
3,933.20
2,633.10
1,900.20
3,607.20
Other Current Liabilities
5,828.70
4,312.50
6,021.20
3,492.70
3,981.20
Total Current Liabilities
9,280.70
13,705.90
11,386.10
13,888.80
13,284.60
Long-Term Debt
505.60
17,593.70
18,436.70
10,013.60
15,736.30
Provision for Risks & Charges
108.30
91.20
61.90
47.50
37.90
Deferred Taxes
4,340.40
5,634.40
5,127.30
4,771.20
3,003.40
Other Liabilities
6,006.90
140.80
10,634.40
14,900.30
16,045.70
Total Liabilities
20,242.00
37,165.90
45,646.40
43,621.50
48,108.00
Common Equity (Total)
44,818.60
31,965.80
44,162.70
40,453.60
16,957.90
Total Shareholders' Equity
44,818.60
31,965.80
44,162.70
40,453.60
16,957.90
Total Equity
44,818.60
31,965.80
44,162.70
40,453.60
16,957.90
Liabilities & Shareholders' Equity
65,060.60
69,131.70
89,809.10
84,075.10
65,065.80

About Bionomics

View Profile
Address
31 Dalgleish Street
Thebarton South Australia (SA) 5031
Australia
Employees -
Website http://www.bionomics.com.au
Updated 07/08/2019
Bionomics Ltd. is a clinical stage biopharmaceutical company, which discovers and develops therapeutics for cancer and diseases of the central nervous system. The company operates through following segments: Drug Discovery and Development, and Contract Services. The Drug discovery and development segment engages in the discovery, development and commercialization of compounds to match a target product profile.